Targeting c-Met in melanoma: Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy

Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Etnyre, Deven, Stone, Amanda L, Fong, Jason T, Jacobs, Ryan J, Uppada, Srijayaprakash B, Botting, Gregory M, Rajanna, Supriya, Moravec, David N, Shambannagari, Manohar R, Crees, Zachary, Girard, Jennifer, Bertram, Ceyda, Puri, Neelu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128856/
https://www.ncbi.nlm.nih.gov/pubmed/24914950
http://dx.doi.org/10.4161/cbt.29451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128856/
https://www.ncbi.nlm.nih.gov/pubmed/24914950
http://dx.doi.org/10.4161/cbt.29451

Ejemplares similares